(1) Direct-to-consumer (DTC) pharmaceutical sales are the most promising drug-pricing reform in years. They cut out middlemen, expose real prices, and let patients buy medicine like consumers—not pawns in a rebate game. It works so well the government is getting in with TrumpRX.
Justin Leventhal
@JustinLeventhal
Senior Policy Analyst at The American Consumer Institute.
259 Following 90 Followers 518 Posts
Latest posts 5
(1) For years, pharmacy benefit managers (PBMs) have operated in a black box—deciding which drugs patients get and what they cost, while no one can see the real costs. The PBM provisions in the Consolidated Appropriations Act of 2026 start to crack that box open.
Wondering what is happening in antitrust in modern America? Check out @consumerpal and @InsideSourcesDC discussion tomorrow at the National Press Club in person or online.
In person: eventbrite.com/e/antitrust-in…
Online: eventbrite.com/e/102092595601…
In person: eventbrite.com/e/antitrust-in…
Online: eventbrite.com/e/102092595601…
Check out ACI's recent comments to FDA on the renewal of modified risk status for snus and its role in helping smokers quit.
theamericanconsumer.org/2024/06/aci-ur…
theamericanconsumer.org/2024/06/aci-ur…
Check out my recent piece on the role of private equity and PBMs in the health care market.
theamericanconsumer.org/2024/05/privat…
theamericanconsumer.org/2024/05/privat…